- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jeanne Tie
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovering epigenetic silencing mechanisms in female stem cells
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Epigenetics – genome wide multiplexed single-cell CUT&Tag assay development
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Mechanisms of Wnt secretion and transport
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Single-cell ATAC CRISPR screening – Illuminate chromatin accessibility changes in genome wide CRISPR screens
- Spatial single-cell CRISPR screening – All in one screen: Where? Who? What?
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structural basing for Wnt acylation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- Validation and application of serological markers of previous exposure to malaria
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- Donors
- WEHI.TV
Pioneering ubiquitin researcher inducted as Academy Fellow
25 May 2023
Professor David Komander has been elected a Fellow of the Australian Academy of Science for his significant research contributions towards unravelling the ubiquitin system.
Ubiquitin is a small protein that acts like a ‘tag’ to tell our cells which proteins use to break down or recycle – a vital process that ensure cells stay healthy and function correctly.
Prof Komander’s findings have transformed the research field’s understanding of how this protein works – unlocking new research areas and leading to drug discovery projects for conditions such as Parkinson’s disease.
At a glance
- Professor David Komander has been elected a Fellow of the Australian Academy of Science for his findings that have shaped our understanding of the ubiquitin system.
- His key discoveries have shaped our understanding of the ubiquitin system and have been translated into drug discovery projects for conditions like Parkinson’s disease.
- Prof Komander is one of 20 scientists elected into the Academy this year, recognised as one of the nation’s most distinguishes scientists for his impactful research.
elected into the Academy this year for his research
contributions towards unravelling the ubiquitin system.
Credit: WEHI
After training as a structural biologist and biochemist in Germany and the UK, Prof Komander moved to WEHI in 2018 to start the first ubiquitin-focused research division in Australia.
He is credited for uncovering how broad and important the ubiquitin system is, highlighting the power and importance of ubiquitin signalling and for helping to unravel fundamental discoveries in a variety of research fields.
Prof Komander, Head of WEHI’s Ubiquitin Signalling Division, said he is both humbled and thrilled to be elected a Fellow of the Academy.
“The ubiquitin field is an extremely exciting one to work in and it has been rewarding to see what my lab has been able to uncover in the past decade,” he said.
“WEHI now has the most comprehensive ubiquitin labs in the southern hemisphere. It is amazing to see more than 50 ubiquitin researchers in one place, using state-of-the-art techniques and fostering vital collaborations to further understand the ubiquitin code.
“In recent years, my lab has leveraged our key insights to understand how ubiquitin signalling is linked to neurodegenerative disorders and other conditions like cancer, with our findings opening new avenues for drug discovery now pursued by academic and biotech efforts.
“Ubiquitin research is inherently disease agnostic, as ubiquitin regulates so many distinct disease processes. Our ultimate goal is to uncover new diagnostics and treatments to stop or delay incurable conditions, like Parkinson’s Disease and other ubiquitin-based disorders.”
The ‘Kiss of Death’ protein
Prof Komander's research focuses on a form of protein modification called 'ubiquitination' which is relevant to a wide range of diseases including cancer, inflammatory diseases, Parkinson's disease and COVID-19.
When proteins are ubiquitinated (modified with a ubiquitin ‘tag’), they are usually quickly destroyed by large cellular machines that disassemble the proteins.
This ‘kiss of death’ is an essential part of life and health, as it ensures broken proteins are removed from circulation, and signals in the body are transmitted.
While this process is essential to removing unwanted or damaged proteins, it can trigger inflammation and stress when it goes awry. Such cellular stress can lead to disease.
For almost two decades, Prof Komander’s research has focussed on unravelling different ubiquitin signals and pathways.
He has led biochemical and molecular studies that enabled research on five previously unstudied ubiquitin chain types, highlighting how complex the ubiquitin system is and its significance in regulating the way our body functions. His methods have been patented and licensed, providing many commercially available reagents.
Prof Komander’s discoveries have often focused on deubiquitinases (DUBs), which remove ubiquitin from proteins and protect proteins from being destroyed.
His work has established DUBs as drug targets to remove unwanted proteins, or to make more beneficial, ‘good’ proteins.
Drug discovery in Parkinson’s disease
Prof Komander’s work has significantly impacted the understanding of Early Onset Parkinson’s Disease (EOPD) and its link to proteins called PINK1 and Parkin, known to play critical roles in EOPD.
In 2021, his team produced a ‘live action’ view of PINK1 in exquisite molecular detail, which showed how the PINK1 progresses from when the protein is initially made, to being activated and functional. The work provided profound insights into Parkinson’s disease.
The work on PINK1 has also paved the way for developing therapeutic agents that ‘switch on’ PINK1 to eventually treat Parkinson’s disease – an incurable condition that affects more than 10 million people worldwide, including more than 80,000 Australians.
Also elected to the Australian Academy of Science this year is WEHI Honorary Fellow Professor Andrew Wilks.
Prof Wilks is CEO of Anaxis Pharma, an innovative joint venture between Synthesis Research and WEHI, focused on developing novel inhibitors/modulators of cell death, specifically an inflammatory form of programmed cell death known as necroptosis.
Media enquiries
M: +61 475 751 811
E: communications@wehi.edu.au
Super Content:
This animation from WEHI.TV illustrates the role of ubiquitin in controlling the fate and activity of other proteins and its involvement in Parkinson’s disease.
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.